Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma.
PMID 18839982 · PMC3204659 · Journal of proteome research · 2008 · 7 claims · 4 setups
Golgi membrane protein 1 (GOLM1/GP73), Annexin IV, and Eps8 are validated candidate biomarkers for cholangiocarcinoma
-
Full-text index only
Proteomic and phospho-proteomic profile of human platelets in basal, resting state: insights into integrin signaling.
PMID 19859549 · PMC2762604 · PloS one · 2009 · 8 claims · 8 setups
A comprehensive platelet proteome of 1507 unique proteins was identified from ten independent human platelet samples, the most comprehensive platelet proteome assembled to date
-
Full-text index only
Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor.
PMID 19657311 · PMC2767399 · Pancreas · 2009 · 8 claims · 6 setups
A homozygous P86S mutation in GCGR is associated with hyperglucagonemia and α cell hyperplasia in the patient
-
Has reproduction
PID1 regulates insulin-dependent glucose uptake by controlling intracellular sorting of GLUT4-storage vesicles.
PMID 30904610 · PMC6624118 · Biochimica et biophysica acta. Molecular basis of disease · 2019 · 8 claims · 8 setups
PID1 serves as an insulin-regulated retention adaptor protein controlling co-translocation of LRP1 and GLUT4 to the adipocyte plasma membrane
-
Full-text index only
Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
PMID 18212748 · PMC2243141 · British journal of cancer · 2008 · 5 claims · 6 setups
LC-MS/MS proteomic analysis of stage I lung adenocarcinoma specimens identified myosin IIA and vimentin as candidate biomarker proteins with signal intensities that differed significantly among patient outcome groups